Intuitive Surgical's ISRG surging cash generation is giving it a meaningful competitive edge as the robotic surgery leader doubles down on innovation. First-half 2026 free cash flow jumped 71% year over year to $1.8 billion, while cash and investments reached $8.6 billion, providing ample financial flexibility to fund research, manufacturing expansion and shareholder returns without compromising growth initiatives.
Management is using that financial strength to widen its technology moat. ISRG is intentionally growing R&D faster than SG&A, expanding manufacturing capacity with new hiring and facility investments, and rolling out more than 100 planned updates for the da Vinci 5 platform. The company is also advancing next-generation programs, including a flexible robotic GI endoscope, while supporting innovation across AI, robotics, imaging and advanced materials. Alongside these investments, ISRG repurchased $379 million of stock during the quarter, underscoring confidence in its long-term outlook.
Peers Update
Boston Scientific BSX delivered another solid quarter, with second-quarter 2026 revenues rising 7.5% to $5.44 billion and adjusted EPS climbing 15% to 86 cents. Growth was driven by strength across Interventional Cardiology, Neuromodulation and Vascular businesses, while the company continued investing in future platforms, including SEISMIQ IVL, hypertension therapies and FARAWAVE Ultra. However, management trimmed its full-year outlook as WATCHMAN and electrophysiology pressures weighed on near-term expectations.
Medtronic MDT continues strengthening its electrophysiology franchise through innovation. The company secured an expanded CE Mark for the Affera Mapping and Ablation System with the Sphere-9 catheter to treat ventricular arrhythmias, making it the first all-in-one mapping and ablation, dual-energy catheter approved in Europe for ventricular ablation. Medtronic also received FDA Breakthrough Device Designation for the technology, while its U.S. Sphere VT pivotal trial is enrolling patients, positioning the platform for future market expansion in a fast-growing cardiac ablation segment.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 34.6% in the year-to-date period compared with the industry’s decline of 6.9%.
Image Source: Zacks Investment Research
From a valuation standpoint, ISRG trades at a price-to-book ratio of 7.15, above the industry average. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ISRG’s 2026 earnings implies a significant 20.3% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).